Maryland 2023 Regular Session

Maryland Senate Bill SB914

Introduced
2/15/23  
Refer
2/15/23  
Refer
3/14/23  
Report Pass
3/23/23  
Engrossed
3/27/23  
Refer
3/28/23  
Refer
4/5/23  
Report Pass
4/7/23  
Enrolled
4/10/23  
Chaptered
5/3/23  

Caption

Hospitals - Testing for Fentanyl (The Josh Siems Act)

Impact

The enactment of SB914 will have considerable implications for healthcare practices within Maryland. Hospitals will be required to integrate fentanyl testing into their emergency department protocols, which may necessitate adjustments in their operational procedures and resource allocations. Importantly, the act allows for exceptions based on a hospital's capacity to conduct such tests, providing flexibility while still emphasizing the urgency of addressing the fentanyl crisis. Reporting obligations to the state health department are also established, ensuring that data on fentanyl-related incidents is systematically collected and monitored.

Summary

Senate Bill 914, known as The Josh Siems Act, addresses the critical issue of fentanyl overdoses by mandating that hospitals conduct rapid urine tests for fentanyl in patients receiving emergency care for known or suspected drug overdoses. This requirement aims to improve response times in identifying fentanyl exposure, which is crucial since fentanyl is a highly potent opioid linked to a significant number of overdose deaths. The act stipulates that hospitals include fentanyl testing as part of their standard drug screening procedures, thereby increasing the likelihood of early detection and intervention in overdose cases.

Sentiment

The general sentiment surrounding SB914 has been positive, reflecting a collective recognition of the need for proactive measures to combat the opioid epidemic. Supporters view the bill as a necessary step toward enhancing public health safety and responding effectively to the increasing rate of fentanyl overdoses. However, there are concerns from some healthcare professionals regarding the potential strain on hospital resources and the implications of mandatory testing for facilities that may lack adequate equipment or staffing for rapid testing.

Contention

While the bill has garnered significant support, notable points of contention include questions over the feasibility of uniform implementation across all hospitals, especially those in rural areas with limited resources. Critics emphasize the need for additional support from the state to ensure that all emergency departments can meet the new testing requirements. Furthermore, there is ongoing debate regarding the balance between public health initiatives and the autonomy of healthcare facilities, particularly in adapting to new regulatory measures while maintaining quality patient care.

Companion Bills

MD HB811

Crossfiled Hospitals - Testing for Fentanyl (The Josh Siems Act)

Previously Filed As

MD HB811

Hospitals - Testing for Fentanyl (The Josh Siems Act)

MD HB5456

HOSPITALS-FENTANYL TESTING

MD HB1626

HOSPITALS-FENTANYL TESTING

MD SB1209

Hospitals; fentanyl testing

MD HB2742

Hospitals; urine drug screening to include testing for fentanyl.

MD H1195

Fentanyl Testing

MD A4057

Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

MD S3274

Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

MD H745

Mandate Fentanyl Testing/Hospital ER Patients

MD S3789

Requires hospital urine drug screenings to include test for fentanyl.

Similar Bills

No similar bills found.